Open Access
Subscription or Fee Access
SARS-CoV-2: A Review
Abstract
The emergence of coronavirus outbreak caused by SARS-CoV-2 has claimed lakhs of human lives and continues to be a potential danger for the world. Initial cases were detected in Wuhan, China, and over the period, the virus spread to various countries. Many nations where the spread of infection was high were forced to shut offices, educational institutions, and transportation by imposing lockdown for months. SARS-CoV-2 is genetically similar to the SARS-CoV-1 and spreads via air from the coughing and sneezing of the infected individual. The virus proliferates inside the host’s body, and signs of infection such as fever, headache, breathing difficulty, less oxygen saturation begin to appear anywhere between 1 to 2 weeks. People with comorbidities such as hypertension, diabetes, pulmonary and heart disorders are usually at a higher risk than normal ones. The SARS-CoV-2 has mutated multiple times; however, the Delta variant poses a significant threat due to its increased virulence. Owing to the development in science, various recombinant and m-RNA vaccines are available which prepare and safeguard the human body against COVID-19 infection.
Keywords
References
Kooshkaki O, Derakhshani A, Conradie AM, et al. Coronavirus Disease 2019: A Brief Review of the Clinical Manifestations and Pathogenesis to the Novel Management Approaches and Treatments. Front Oncol. 2020; 10: 2031p.
Boopathi S, Poma AB, Kolandaivel P. Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment. J Biomol Struct Dyn. 2020: 1–10p.
Pal M, Berhanu G, Desalegn C, Kandi V. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update. Cureus. 2020; 12(2).
El-Sayed A, Kamel M. Coronaviruses in humans and animals: the role of bats in viral evolution. Environ Sci Pollut Res. 2021; 28(16): 19589–600p.
Dhand R, Li J. Coughs and Sneezes: Their Role in Transmission of Respiratory Viral Infections, Including SARS-CoV-2. Am J Respir Crit Care Med. 2020; 202(5): 651–9p.
Transmission of SARS-CoV-2: implications for infection prevention precautions. World Health Organization. [Internet] [cited 2021 July 23]. Available from: https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions
Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 2020; 172(9): 577–82p.
Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection. Ann Intern Med. 2020; 173(3): 362–7p.
Li F. Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu Rev Virol. 2016; 3(1): 237–61p.
Belouzard S, Millet JK, Licitra BN, Whittaker GR. Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike Protein. Viruses. 2012; 4(6): 1011–33p.
Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong J-C, Turner AJ, et al. Response by Gheblawi et al to Letter Regarding Article, “Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2.” Circ Res. 2020; 127(2).
Subbarao K, Mahanty S. Respiratory Virus Infections: Understanding COVID-19. Immunity. 2020; 52(6): 905–9p.
Almaghaslah D, Kandasamy G, Almanasef M, Vasudevan R, Chandramohan S. Review on the coronavirus disease (COVID‐19) pandemic: Its outbreak and current status. Int J Clin Pract 2020; 74(11).
Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020; 55(3): 105924p.
Srivastava S, Banu S, Singh P, Sowpati DT, Mishra RK. SARS-CoV-2 genomics: An Indian perspective on sequencing viral variants. J Biosci. 2021; 46(1).
V’kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2020; 19(3): 155–70p.
Sohrabi C, Alsafi Z, O'Neill N, Khan M, Kerwan A, Al-Jabir A, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020; 76: 71–6p.
The Visual and Data Journalism Team. Covid map: Coronavirus cases, deaths, vaccinations by country. BBC News. BBC; 2021. [Internet] [cited 2021 July 23]. Available from: https://www.bbc.com/news/world-51235105
Taxonomy browser (Human coronavirus OC43). National Center for Biotechnology Information. U.S. National Library of Medicine. [Internet] [cited 2021 July 23]. Available from: https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?lvl=0&id=31631
Taxonomy. International Committee on Taxonomy of Viruses (ICTV). Available from: https://talk.ictvonline.org/taxonomy
Masters PS. The Molecular Biology of Coronaviruses. Adv Virus Res 2006:193–292.
Lalchhandama K. The chronicles of coronaviruses: the electron microscope, the doughnut, and the spike. Sci Vis. 2020; 20(2): 78–92p.
Huang Y, Yang C, Xu X-feng, Xu W, Liu S-wen. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020; 41(9): 1141–9p.
Won, J.-H., & Lee, H. The current status of drug repositioning and vaccine developments for the COVID-19 pandemic. Int. J. Mol. Sci. 2020; 21(24), 9775p.
McBride R, van Zyl M, Fielding B. The Coronavirus Nucleocapsid Is a Multifunctional Protein. Viruses. 2014; 6(8): 2991–3018p.
Neuman BW, Kiss G, Kunding AH, Bhella D, Baksh MF, Connelly S, et al. A structural analysis of M protein in coronavirus assembly and morphology. J Struct Biol. 2011; 174(1): 11–22p.
Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J. 2019; 16(1).
Fehr AR, Perlman S. Coronaviruses: An Overview of Their Replication and Pathogenesis. Coronaviruses. 2015: 1–23p.
Acter T, Uddin N, Das J, Akhter A, Choudhury TR, Kim S. Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency. Sci Total Environ. 2020; 730: 138996p.
Coronavirus. World Health Organization. World Health Organization. [Internet] [cited 2021 July 23]. Available from: https://www.who.int/health-topics/coronavirus#tab=tab_3
Coronavirus Disease 2019 Testing Basics. U.S. Food and Drug Administration. FDA. [Internet] [cited 2021 July 23]. Available from: https://www.fda.gov/consumers/consumer-updates/coronavirus-disease-2019-testing-basics
Kevadiya BD, Machhi J, Herskovitz J, Oleynikov MD, Blomberg WR, Bajwa N, et al. Diagnostics for SARS-CoV-2 infections. Nat Mater. 2021; 20(5): 593–605p.
How to Protect Yourself & Others. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention. Available from: https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html
Advice for the public on COVID-19. World Health Organization. World Health Organization. [Internet] [cited 2021 July 23]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public
Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19. U.S. Food and Drug Administration. FDA. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19
FDA Approves First Treatment for COVID-19. U.S. Food and Drug Administration. FDA. [Internet] [cited 2021 July 24]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19
Dondorp AM, Hayat M, Aryal D, Beane A, Schultz MJ. Respiratory Support in COVID-19 Patients, with a Focus on Resource-Limited Settings. Am J Trop Med Hyg. 2020; 102(6): 1191–7p.
Cascella M. Features, Evaluation, and Treatment of Coronavirus (COVID-19). StatPearls. U.S. National Library of Medicine; 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554776/
Kelleni MT. Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment. SN Compr Clin Med. 2021; 3(4): 919–23p.
Chen P-L, Lee N-Y, Cia C-T, Ko W-C, Hsueh P-R. A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs. Front Pharmacol. 2020; 11.
Malhotra P, Khaire NS, Jindal N, Yaddanapudi LN, Sachdev S, Hans R, et al. Use of convalescent plasma for COVID-19 in India: A review & practical guidelines. Indian J Med Res. 2021.
Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020: 4232.
About Variants of the Virus that Causes COVID-19. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention. [Internet] [cited 2021 July 24]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant.html
SARS-CoV-2 Variant Classifications and Definitions. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention. [Internet] [cited 2021 July 24]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html
Tracking SARS-CoV-2 variants. World Health Organization. World Health Organization. [Internet] [cited 2021 July 24]. Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
Mucormycosis. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention; 2021. [Internet] [cited 2021 July 24]. Available from: https://www.cdc.gov/fungal/diseases/mucormycosis/index.html
Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of Mucormycosis. Clin Infect Dis. 2012; 54(suppl 1): 16-22p.
Prakash H, Chakrabarti A. Global Epidemiology of Mucormycosis. J Fungi (Basel). 2019; 5(1): 26p.
Mucormycosis. NORD (National Organization for Rare Disorders). 2018. [Internet] [cited 2021 July 24]. Available from: https://rarediseases.org/rare-diseases/mucormycosis/
Mehta S, Pandey A. Rhino-Orbital Mucormycosis Associated With COVID-19. Cureus. 2020.
Kontoyiannis DP, Lewis RE, Lotholary O, Spellberg B, Petrikkos G, Roillides E, et al. Future Directions in Mucormycosis Research. Clin Infect Dis. 2012; 54(suppl 1).
Skiada A, Lanternier F, Groll AH, Pagano L, Zimmerli S, Herbrecht R, et al. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica. 2012; 98(4): 492–504p.
Diagnosis and Testing of Mucormycosis. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention; 2021. [Internet] [cited 2021 July 24]. Available from: https://www.cdc.gov/fungal/diseases/mucormycosis/diagnosis.html
Treatment for Mucormycosis. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention; 2021. [Internet] [cited 2021 July 24]. Available from: https://www.cdc.gov/fungal/diseases/mucormycosis/treatment.html
Common Components of Vaccines. BioRender App. [Internet] [cited 2021 July 24]. Available from: https://app.biorender.com/biorender-templates/figures/5e99f5395fd61e0028682c01/t-5ec6b950af5ada00b016ccd1-common-components-of-vaccines
Bharat Biotech-Vaccines & Bio-Therapeutics Manufacturer in India. [Internet] [cited 2021 July 25]. Available from: https://www.bharatbiotech.com/covaxin.html
Darbar S, Saha S and Agarwal S. “COVID19 Vaccine: COVAXIN®-India’s First Indigenous Effective Weapon to Fight against Coronavirus (A Review)”. Parana Journal of Science and Education. 2021; 7: 1-9p.
Serum Institute Of India - ChAdOx1 nCoV- 19 Corona Virus Vaccine (Recombinant) - COVISHIELD. [Internet] [cited 2021 July 25]. Available from: https://www.seruminstitute.com/product_covishield.php
Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov, 2018; 17(4): 261–79p.
Moderna COVID-19 Vaccine. U.S. Food and Drug Administration. FDA. [Internet] [cited 2021 July 25]. Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine
One of the world's premier biopharmaceutical companies. Pfizer. [Internet] [cited 2021 July 25]. Available from: https://www.pfizer.com/
Pfizer-BioNTech COVID-19 Vaccine. U.S. Food and Drug Administration. FDA. [Internet] [cited 2021 July 25]. Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine
Johnson & Johnson. Content Lab U.S. [Internet] [cited 2021 July 25]. Available from: https://www.jnj.com/johnson-johnson-covid-19-vaccine-authorized-by-u-s-fda-for-emergency-usefirst-single-shot-vaccine-in-fight-against-global-pandemic
Janssen COVID-19 Vaccine. U.S. Food and Drug Administration. [Internet] [cited 2021 July 25]. Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine
Refbacks
- There are currently no refbacks.